|
Activity Number:
|
409
- Complex Innovative Approaches in Emerging Neurodegenerative / Neuroimaging Drug Developments
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Wednesday, August 5, 2020 : 1:00 PM to 2:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #312809
|
|
|
Title:
|
Alternatives to MMRM for Preclinical Alzheimer’s Clinical Trials
|
|
Author(s):
|
Michael C Donohue* and Gopalan Sethuraman and Oliver Langford and Wenyi Lin and Philip S Insel and Wesley Thompson and Rema C Raman and Reisa Sperling and Paul S Aisen
|
|
Companies:
|
University of Southern California and University of Southern California and University of Southern California and University of California, San Diego and Lund University and University of California, San Diego and University of Southern California and Harvard Medical School and University of Southern California
|
|
Keywords:
|
Mixed Model for Repeated Measures (MMRM);
Alzheimer's Clinical Trials;
Longitudinal Models
|
|
Abstract:
|
The Mixed Model for Repeated Measures (MMRM) is the most commonly used approach for assessing treatment effects in Alzheimer’s clinical trials. An alternative nonlinear Disease Progression Model (DPM) which assumes the ratio of group means is fixed over time has been proposed for Autosomal Dominant Alzheimer's clinical trials. We compare, with analysis on related natural history data, and with simulations, nonlinear and alternative linear mean structures and various correlation structures for assessing treatment effects in Preclinical Alzheimer’s clinical trials.
|
Authors who are presenting talks have a * after their name.
